Clinical Trial Update: The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy [Phase 3]

View source ↗

Summary

A Phase 3 trial (GUARD Trial) evaluating prevention of Proliferative vitreoretinopathy has completed with results posted in 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Proliferative Vitreoretinopathy

Drugs mentioned

• Aldeyra Therapeutics investigational compound

Snippet

Sponsor: Aldeyra Therapeutics, Inc. | Conditions: Proliferative Vitreoretinopathy | Phase 3 | Status: COMPLETED | Results posted: 2025-07-09